ABSTRACT
Introduction We aimed to estimate vaccine effectiveness against infection (VE- infection) and infectiousness (VE-infectiousness) in a household setting during Delta and Omicron. Knowing these effects can aid policy makers in deciding which groups to prioritize for vaccination.
Methods Participants with a positive SARS-CoV-2 test were asked about COVID-19 vaccination status and SARS-CoV-2 testing of their household members one month later. VE-infection and VE-infectiousness was estimated using GEE logistic regression adjusting for age and vaccination status, calendar week and household size.
Results 3,409 questionnaires concerning 4,123 household members were included. During the Delta-period, VE-infection of primary series was 47% (95% CI: −27%-78%) and VE-infectiousness of primary series was 70% (95% CI: 28%-87%). During the Omicron-period, VE-infection was −36% (95% CI: −88%-1%) for primary series and −30% (95% CI: −80%-6%) for booster vaccination. The VE-infectiousness was 45% (95% CI: −14%-74%) for primary series and 64% (95% CI: 31%-82%) for booster vaccination.
Discussion Our study shows that COVID-19 vaccination is effective against infection with SARS-CoV-2 Delta and against infectiousness of SARS-CoV-2 Delta and Omicron. Estimation of VE against infection with SARS-CoV-2 Omicron was limited by several factors. Our results support vaccination for those in close contact with vulnerable people to prevent transmission.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://trialsearch.who.int/Trial2.aspx?TrialID=NL9279
Funding Statement
This study was funded by the Dutch Ministry of Health, Welfare and Sport
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was provided by the Medical Ethics Committee of the Stichting Beoordeling Ethiek Biomedisch Onderzoek, Assen, the Netherlands.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data produced in this manuscript are available in aggregated and anonymized form upon reasonable request to the authors.
